Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Buyse

Showing results (11-20 of 227) with videos related to

Pageof 23
Sort By:
Bulletin Du Cancer|April 19, 2012
[Criteria and endpoints in advanced prostate cancer]Pascal Piedbois, Marc Buyse
Current Opinion in Oncology|March 12, 2013
Omics-based clinical trial designsMarc Buyse, Stefan Michiels
Recherche En Soins Infirmiers|July 9, 2010
[Meta-analysis based on individual patient data: example of advanced colorectal cancer]Pascal Piedbois, Marc Buyse
Current Opinion in Oncology|June 6, 2008
Endpoints and surrogate endpoints in colorectal cancer: a review of recent developmentsPascal Piedbois, Marc Buyse
International Journal of Clinical Oncology|November 19, 2015
Fraud in clinical trials: complex problem, simple solutions?Junichi Sakamoto, Marc Buyse
Annals of the Rheumatic Diseases|January 28, 2025
Bridging the gap: tackling the challenge of limited progressors in clinical trials aimed at slowing the transition from early preradiographic to established osteoarthritisFrancis Berenbaum, Marc Buyse
Pharmaceutical Statistics|November 4, 2006
Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validationTomasz Burzykowski, Marc Buyse
Current Opinion in Oncology|June 17, 2020
Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpointsEverardo D Saad, Marc Buyse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?Everardo D Saad, Marc Buyse
Cardiology|May 21, 2011
Assessment of statistical heterogeneity in the PLATO trialMarc Buyse, Ian C Marschner
Pageof 23

Showing results (11-20 of 227) with videos related to

Sort By:
Pageof 23
Bulletin Du Cancer|April 19, 2012
[Criteria and endpoints in advanced prostate cancer]Pascal Piedbois, Marc Buyse
Current Opinion in Oncology|March 12, 2013
Omics-based clinical trial designsMarc Buyse, Stefan Michiels
Recherche En Soins Infirmiers|July 9, 2010
[Meta-analysis based on individual patient data: example of advanced colorectal cancer]Pascal Piedbois, Marc Buyse
Current Opinion in Oncology|June 6, 2008
Endpoints and surrogate endpoints in colorectal cancer: a review of recent developmentsPascal Piedbois, Marc Buyse
International Journal of Clinical Oncology|November 19, 2015
Fraud in clinical trials: complex problem, simple solutions?Junichi Sakamoto, Marc Buyse
Annals of the Rheumatic Diseases|January 28, 2025
Bridging the gap: tackling the challenge of limited progressors in clinical trials aimed at slowing the transition from early preradiographic to established osteoarthritisFrancis Berenbaum, Marc Buyse
Pharmaceutical Statistics|November 4, 2006
Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validationTomasz Burzykowski, Marc Buyse
Current Opinion in Oncology|June 17, 2020
Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpointsEverardo D Saad, Marc Buyse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?Everardo D Saad, Marc Buyse
Cardiology|May 21, 2011
Assessment of statistical heterogeneity in the PLATO trialMarc Buyse, Ian C Marschner
Pageof 23